Mechanism Of Action
Board of Directors
Scientific Advisory Board
The most common liver disorder
Associated with metabolic syndrome and cardiovascular disease
An innovative first-in-class drug candidate
Consists of two naturally occurring components
The fruit of collaborative worldwide extensive research
Learn about Non Alcoholic Fatty Liver Disease (NAFLD) – a disease affecting 30% of the population in developed countries.
Fatty acid-bile acid conjugates (FABACs) are a new family of small synthetic molecules initially designed to solubilize biliary cholesterol.
Galmed Pharmaceuticals is developing innovative drugs for the treatment of lipids and liver diseases.
Recent News & Events
Galmed files for NASDAQ IPO
International Conference in Memory of the Late Professor Tuvia Gilat
Phase II Aramchol Clinical Trial Results
© Copyright Galmed 2015